BiOptix Announces a New SPR Technology for Antibody Manufacturers and Researchers
Boulder, Colorado/San Diego, CA, USA
BiOptix announced today that it will be showcasing the new BiOptix 404pi at IBC"s 23rd Annual Antibody Engineering and Therapeutics Conference in San Diego. The conference, which runs December 2–6, 2012, is one of the preeminent technology symposia in the world for the international antibody development and research community.
“The new BiOptix 404pi, the first commercially available SPR instrument to incorporate
BiOptix technology allows for the simultaneous monitoring of multiple analytes in a single sample. This new class of SPR instrumentation from BiOptix has been designed to measure protein/protein and
Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip’s gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel
BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented
For more information, visit www.bioptix.com